Informations

The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation…

The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC) and Best of ASCO® 2025 China (BOC/BOA) will be held on July 4–5 in Nanjing. This year’s event coincides with the 10th anniversary of the China Clinical Oncology Annual Research Progress publication—marking a key milestone in China’s oncology journey. Over the past decade,…

At the recent “Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association,” Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier…

Oncology Frontier invited Professor Li for an in-depth interview to discuss major research updates on TROP2 ADCs in the treatment of mTNBC presented at ASCO 2025 and their clinical implications,…

DB-09 Redefines the First-Line Standard in Advanced Disease Oncology Frontier: The DB-09 study presented at ASCO 2025 has drawn significant attention and set a new benchmark for median PFS in…

Oncology Frontier: In the context of adjuvant therapy for early-stage TNBC, the Fudan Oncology team previously demonstrated the value of adding carboplatin in the PATTERN study (PCb vs. CEF-T). However,…

Fifth Bincheng Multidisciplinary Breast Cancer Conference Oncology Frontier: The DB-09 study was one of the highlights at ASCO 2025 and marked a breakthrough in the treatment of HER2-positive metastatic breast…